MétaCan
Menu
Back to cohort
Record W2913552344 · doi:10.1093/ecco-jcc/jjy222.195

P071 Supporting extrapolation of indications for ABP 501, the first adalimumab biosimilar: focus on Crohn’s disease

2019· article· en· W2913552344 on OpenAlexaff
Smita Halder, Waliul I. Khan, X Wang, Scott Kuhns, Heather Sweet, Walter Reinisch, Helen J. McBride

Bibliographic record

VenueJournal of Crohn s and Colitis · 2019
Typearticle
Languageen
FieldImmunology and Microbiology
TopicBiosimilars and Bioanalytical Methods
Canadian institutionsMcMaster University
Fundersnot available
KeywordsAdalimumabAntibody-dependent cell-mediated cytotoxicityTumor necrosis factor alphaMedicinePeripheral blood mononuclear cellPharmacologyImmunologyCytotoxicityChemistryCancer researchMonoclonal antibodyAntibodyIn vitroBiochemistry

Abstract

fetched live from OpenAlex

ABP 501 (EU: AMGEVITA® [adalimumab]; US: AMJEVITA™ [adalimumab-atto]) is the first approved biosimilar to adalimumab (HUMIRA®). The primary mechanism of action (MOA) of adalimumab is mediated by binding to soluble tumour necrosis factor (TNF)-α, inhibiting its proinflammatory signalling. Secondary mechanisms mediated by binding to membrane bound (mb) TNF-α may play a role in inflammatory bowel disease (IBD) and include reverse signalling, mixed lymphocyte reactions (MLRs) and effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). To support extrapolation to IBD, specific ex vivo functional studies explored the similarity of ABP 501 to adalimumab reference product (RP) in these mechanisms. Multiple lots of ABP 501 and RP sourced from the USA (US) and the European Union (EU) were compared. Binding of ABP 501 and RP to soluble TNF (sTNF) α and mbTNF α were tested. Blocking of TNF α-induced caspase activation, IL-8 secretion and lymphotoxin (LT)-α (TNF-β) bioactivity (ie, specificity) were also assessed. To confirm similarity in Fc-mediated functions, ADCC using engineered NK92 cells expressing the high-affinity variant of FcgRIIIa (158V) and CDC were tested. ADCC was also assessed in peripheral blood mononuclear cells (PBMCs) isolated from healthy volunteers and patients with Crohn’s disease. Relative binding to sTNF α was similar [ABP 501, 108%; RP (EU), 111%; RP (US), 112%], demonstrating similarity in potency. Relative binding to mbTNF α was also similar [ABP 501, 103%; RP (EU), 106%; RP (US), 105%]. Relative activity in reverse signalling was similar [ABP 501, 99%; RP (EU), 99%; RP (US), 98%]. Relative activity was similar in NK92 ADCC [ABP 501, 85%; RP (EU), 87%; RP (US), 86%] and CDC [ABP 501, 100%; RP (EU), 94%; RP (US), 94%]. PBMCs isolated from healthy volunteers and patients with Crohn’s disease showed similar, dose-dependent ADCC activity with all three agents. ABP 501 adalimumab biosimilar has previously been shown to be highly similar to adalimumab RP in several analytical assessments, clinical pharmacokinetics, efficacy, safety and immunogenicity. We have demonstrated that similarity extends to biological activity across key MOAs, including those mediated through mbTNF-α that may be important for the efficacy of adalimumab in IBD. Coupled with previously reported effector function and reverse signalling assessments, ex vivo ADCC activity in PBMCs isolated from healthy volunteers and patients with Crohn’s disease contribute to the totality of evidence supporting efficacy of ABP 501 in IBD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.811
Threshold uncertainty score0.339

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.293
Teacher spread0.276 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and ColitisSame topicBiosimilars and Bioanalytical MethodsFrench-language works237,207